Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (guinea-pig, rat, rabbit).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 383,500 |
50 mg | 約6-8 週間 | ¥ 500,500 |
100 mg | 約6-8 週間 | ¥ 643,000 |
説明 | Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (guinea-pig, rat, rabbit). |
別名 | F12511, L-0081, F-12511, L0081 |
分子量 | 469.72 |
分子式 | C29H43NO2S |
CAS No. | 191791-65-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(RS)-Eflucimibe 191791-65-8 Eflucimibe F12511 L 0081 L-0081 F 12511 F-12511 L0081 Inhibitor inhibitor inhibit